is vomiting a side effect of semaglutide Can Cause Pancreatitis? Symptoms and Risk Factors Wegovy Side Effects and How

FDA Clears First Oral GLP-1 for Weight Loss On December 22, 2025, the FDA approved Novo Nordisks once-daily Wegovy pill (25 mg semaglutide), the first oral GLP-1 receptor agonist indicated for chronic weight management and cardiovascular risk reduction in adults with obesity or overweight plus at least one weight-related comorbidity

The patients were not keen in getting the above tests done

Physical activity promotes heart health, lowers blood cholesterol levels, and helps maintain stable blood sugar levels

You can gradually build up from there, aiming for 150 minutes throughout the week

You may not feel thirsty even when your body needs fluids